UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	ırden
hours per response	0.4

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	e Responses)														
1. Name and Address of Reporting Person * Yarema Kristin (Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900 (Street) SOUTH SAN FRANCISCO, CA 94080			2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
			1 1	Date of Earliest Transaction (Month/Day/Year) 02/18/2020 High Amendment, Date Original Filed(Month/Day/Year)						X Officer (give title below) Other (specify below)					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu										s Acquire	
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year) any	tion I	Date, if C		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		f (D) Ow Tra	Amount of Securities Beneficially whed Following Reported ansaction(s)		O F	Ownership of Form:	Beneficial
			(Month/Day/Year)		Code	V A	(A) or (D)	Price	(Instr. 3 and 4)		(I	Direct (D) Ownership or Indirect (Instr. 4) (I) (Instr. 4)			
			Table II -					a curren	orm are not re tly valid OMB sed of, or Benef evertible securi	control r	number.	nless the f	orm displays		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Table II - 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	etion	alls, warr 5. Numbe	r of e (A) ed of	a currentired, Disposoptions, con	sed of, or Benefacertible securions and Date	control ricially Ow	number. med and Amount ying	8. Price of		10. Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	etion	5. Number Derivative Securities Acquired or Dispos (D) (Instr. 3, 4	r of ee (A) eed of	a current ared, Dispos options, con 6. Date Exe Expiration	sed of, or Benefacertible securi reisable and Date y/Year)	ficially Owties) 7. Title ar of Underl Securities	number. med and Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownershi (Instr. 4)

		Relationships				
Reporting Owner Name / Address	Director	. 10% Owner	Officer	Other		
Yarema Kristin C/O ATARA BIOTHERAPEUTICS 611 GATEWAY BLVD., SUITE 90 SOUTH SAN FRANCISCO, CA 940	Ó		Chief Commercial Officer			

Signatures

/s/ David Tucker, Attorney-in-Fact for Kristin Yarema	02/19/2020
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the option vest on February 18, 2021 and the remaining shares vest in equal monthly installments over the following 36 months months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.